bioAffinity Technologies advances CyPath Lung for post-treatment surveillance
bioAffinity Technologies said it is advancing CyPath Lung as a noninvasive surveillance option for lung cancer patients after curative-intent treatment.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.